Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Clin Cancer Res. 2018 Jan 12;24(7):1727–1733. doi: 10.1158/1078-0432.CCR-17-0721

Table 2.

TP53 mutation status (UTMDACC ENE cohort).

PTa LNb
Patient Amino Acid EA Score Typec Amino Acid EA Score Typec
1 R248Q 78.95 HR 0 Wt
2 R342* Other R342* Other
3 E286A 87.02 HR E286A 87.02 HR
4 0 Wt 0 Wt
5 0 Wt L111fs, Y205C 77.88 HR
6 G245S 86.45 HR G245S 86.45 HR
7 0 Wt 0 Wt
8 L137fs Other L137fs Other
9 0 Wt 0 Wt
10 Y107* Other Y107* Other
11 0 Wt 0 Wt
12 R248Q 78.95 HR R248Q 78.95 HR
13 Y220C 72.52 LR 0 Wt
14 0 Wt 0 Wt
15 0 Wt E285K 69.87 LR
16 D207fs Other D207fs Other
17 H179R 81.91 HR H179R 81.91 HR
a

PT: Primary Tumor

b

LN: Lymph Node Metastasis

c

TP53 mutations divided into 4 groups based on EA system: Wt (Wild Type), LR (Low-risk missense mutation), HR (High-risk missense mutation), Other (any type of mutations except missense mutations)